Literature DB >> 23641696

Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.

Keyang Xu1, Luna Liu, Randall Dere, Elaine Mai, Rebecca Erickson, Angela Hendricks, Kedan Lin, Jagath R Junutula, Surinder Kaur.   

Abstract

BACKGROUND: Antibody-drug conjugates (ADCs) are a new class of cancer therapeutics that deliver potent cytotoxins specifically to tumors to minimize systemic toxicity. However, undesirable release of covalently linked drugs in circulation can affect safety and efficacy. The objective of this manuscript was to propose and assess the assays that allow for the characterization of the drug deconjugation in plasma/serum.
RESULTS: ADCs of three main drug conjugation platforms, linked via lysine, site-specific engineered cysteine or reduced interchain disulfide cysteine residues, were analyzed using affinity capture for sample enrichment coupled with LC-MS or hydrophobic interaction chromatography-UV for detection. These novel approaches enabled measurement of the relative abundance of individual ADC species with different drug-to-antibody ratios, while maintaining their structural integrity.
CONCLUSION: The characterization data generated by affinity capture LC-MS or hydrophobic interaction chromatography-UV provided critical mechanistic insights into understanding the stability and bioactivity of ADCs in vivo, and also helped the development of appropriate quantitative ELISAs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23641696     DOI: 10.4155/bio.13.66

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  10 in total

1.  Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry.

Authors:  Jintang He; Shang-Fan Yu; Sharon Yee; Surinder Kaur; Keyang Xu
Journal:  MAbs       Date:  2018-07-26       Impact factor: 5.857

2.  Utility of Ion Mobility Mass Spectrometry for Drug-to-Antibody Ratio Measurements in Antibody-Drug Conjugates.

Authors:  Richard Y-C Huang; Ekaterina G Deyanova; David Passmore; Vangipuram Rangan; Shrikant Deshpande; Adrienne A Tymiak; Guodong Chen
Journal:  J Am Soc Mass Spectrom       Date:  2015-06-30       Impact factor: 3.109

3.  A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.

Authors:  Brendan Bender; Douglas D Leipold; Keyang Xu; Ben-Quan Shen; Jay Tibbitts; Lena E Friberg
Journal:  AAPS J       Date:  2014-06-11       Impact factor: 4.009

Review 4.  Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.

Authors:  Amrita V Kamath; Suhasini Iyer
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

Review 5.  Challenges and advances in the assessment of the disposition of antibody-drug conjugates.

Authors:  Amrita V Kamath; Suhasini Iyer
Journal:  Biopharm Drug Dispos       Date:  2015-06-08       Impact factor: 1.627

Review 6.  Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates.

Authors:  Xiaoyu Zhu; Shihan Huo; Chao Xue; Bo An; Jun Qu
Journal:  J Pharm Anal       Date:  2020-05-23

7.  Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.

Authors:  Clemence Pouzin; Leonid Gibiansky; Nathalie Fagniez; Mustapha Chadjaa; Michel Tod; Laurent Nguyen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-02-15       Impact factor: 2.410

Review 8.  Potential of antibody-drug conjugates (ADCs) for cancer therapy.

Authors:  Hany E Marei; Carlo Cenciarelli; Anwarul Hasan
Journal:  Cancer Cell Int       Date:  2022-08-13       Impact factor: 6.429

9.  Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency.

Authors:  Dian Su; Donglu Zhang
Journal:  Front Pharmacol       Date:  2021-06-23       Impact factor: 5.810

10.  2-(Maleimidomethyl)-1,3-Dioxanes (MD): a Serum-Stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation.

Authors:  Igor Dovgan; Sergii Kolodych; Oleksandr Koniev; Alain Wagner
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.